Trial Profile
Precision Dosing of Alemtuzumab for Allogeneic Hematopoietic Cell Transplantation in Non-Malignant Diseases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Fludarabine; Melphalan
- Indications Graft-versus-host disease
- Focus Pharmacokinetics
- 28 Jun 2021 Results from NCT03302754 and other study; assessing alemtuzumab population PK/PD and individualized subcutaneous dosing schemes to achieve this optimal level for pediatric patients, published in the British Journal of Clinical Pharmacology
- 03 Oct 2019 Status changed from recruiting to completed.
- 10 Oct 2017 New trial record